Lancet: Nivolumab for treatment of stage IV melanoma

Nivolumab combined with Ipilimumab is an important immunotherapy treatment for advanced, non-rectoctable or metastatic melanoma, but there is no data available for this option in patients with stage IV melanomaRecently, researchers evaluated the efficacy of Nivolumab's combination with Ipilimumab or Nivolumab single-drug treatment for stage IV melanomathis study for Phase II clinical study, 18-80 years old in stage IV melanoma patients involved, patients after cancer or radiotherapy no signs of disease, random treatment of Nivolumab and Ivolumab (intravenous nivolumab 1 mg/kg every 3 weeks, intravenous lyme every 3 weeks Inject ipilimumab 3 mg/kg 4 times, then intravenously nivolumab 3 mg/kg every 2 weeks), Nivolumab monotherapy (intravenous nivolumab 3 mg/kg every 2 weeks, with placebo at 1-12 weeks) or double placebo treatmentThe main endpoint of the study was the non-recurrence survival rate167 patients participated in the study, including 56 in the Nivolumab and Ipilimumab groups, 59 in the Nivolumab group and 52 in the placebo groupIn the median follow-up of 28.4 months, there was no recurrence in the Nivolumab-Ipilimumab group, while the non-recurrent survival rate was 12.4 months in the Nivolumab group and 6.4 months in the placebo groupIn the Nivolumab-Ipilimumab group, the recurrence risk ratio was 0.23 compared to the placebo group, and the recurrence risk ratio was 0.56 in the Nivolumab group compared to the placebo groupThe 1-year recurrent survival rate was 75% in the Nivolumab-Ipilimumab group, 70% in 2 years, 52% in the Nivolumab group and 42% in 2 years, and 32% in the placebo group for 1 year and 14% for 2 yearsTreatment-related level 3-4 adverse events were reported in 71% of patients in the Nivolumab-Ipilimumab group and 27% of patients in the Nivolumab groupAny level of treatment-related adverse events caused the combined group to stop treatment in 34 cases (62%) and 7 (13%) in the single drug group to stop treatmentThree adverse event deaths were reported, but not treatmentstudies suggest that Nivolumab single-drug or combined Ipilimumab-assisted treatment can significantly improve the non-recurrence survival rate of patients with stage IV melanoma